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ScienceDirectCopper plays a vital role in fundamental cellular functions, and
its concentration in the cell must be tightly regulated, as
dysfunction of copper homeostasis is linked to severe
neurological diseases and cancer. This review provides a
compendium of current knowledge regarding the mechanism
of copper transfer from the blood system to the Golgi
apparatus; this mechanism involves the copper transporter
hCtr1, the metallochaperone Atox1, and the ATPases ATP7A/
B. We discuss key insights regarding the structural and
functional properties of the hCtr1-Atox1-ATP7B cycle,
obtained from diverse studies relying on distinct yet
complementary biophysical, biochemical, and computational
methods. We further address the mechanistic aspects of the
cycle that continue to remain elusive. These knowledge gaps
must be filled in order to be able to harness our understanding
of copper transfer to develop therapeutic approaches with the
capacity to modulate copper metabolism.
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Introduction
Copper, like other metals, has a pivotal role in fundamental
processes of cell function. It takes part in cellular respira-
tion, iron oxidation, pigment formation, neurotransmitter
biosynthesis, antioxidant defense, and connective tissue
formation. Yet, when present at excessive concentrations, it
can endanger the cell’s survival, by causing de-regulated
oxidation of proteins, lipids, and other cellular components,
ultimately leading to injury. Moreover, free Cu ions canCurrent Opinion in Structural Biology 2019, 58:26–33 produce radical oxygen species (ROS), which can lead to
cytotoxic interactions with cell membranes [1–2,3,4].
Insufficient concentrations of copper, in turn, can lead to
metabolic abnormalities, as copper-dependent proteins
drive iron absorption, and a copper deficiency can therefore
lead to iron deficiency. Thus, intracellular pathways of
copper metabolism have evolved to ensure the appropriate
amount of Cu for cell survival.
Broadly, copper follows the following trajectory through
the human body: First, it accumulates in the blood
through diet. Once it has been ingested, it is taken up
from the blood by the copper transporter hCtr1. The
copper is then reduced from its oxidized form, Cu(II), to
the Cu(I) form; the mechanism of reduction is not fully
known, as elaborated in what follows. Then, the trans-
porter translocates the Cu(I) into the cell. Next, specific
Cu(I) chaperones deliver the metal to the appropriate
cellular pathways (Figure 1) [5–8]. One such chaperone is
Atox1, which transfers Cu(I) to its transporting ATPases
in the Golgi apparatus. These ATPases include ATP7A
and ATP7B, which play a biosynthetic role, delivering Cu
(I) to the secretory pathway for metalation of cuproen-
zymes, and a homeostatic role, exporting excess Cu(I)
from the cell. Additional chaperones include CCS, which
is required for Cu(I) incorporation into cytoplasmic
Cu/Zn superoxide dismutase, and Cox17, which delivers
Cu(I) to mitochondrial cytochrome c oxidase.
In what follows, we provide an overview of current
knowledge regarding the hCtr1-Atox1-ATP7B cycle.
The hCtr1-Atox1-ATP7A/B cycle is associated with
Menkes’ disease and with Wilson’s disease, in which
mutations in ATP7A/B disrupt the homeostatic copper
balance, resulting in Cu deficiency or overload, respec-
tively. Beside these rare genetic diseases, the cycle has
been implicated in Alzheimer‘s and Parkinson‘s diseases,
and in anti-cancer drug resistance [1,2,9–12]. Here, we
summarize atomic-level type of information on key resi-
dues that are significant for function, and structural and
kinetic insights on the copper transfer mechanism along
its delivery path from the blood system to the Golgi
apparatus and/or its egress from the cell.
Experimental and computational approaches
used to study copper trafficking
This review compiles information obtained through
diverse experimental and computational methodologies.www.sciencedirect.com
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The human copper cycle system.These latter include X-ray crystallography and nuclear
magnetic resonance (NMR) spectroscopy, which were
used to solve the 3D structures of the chaperone Atox1
[13] and the metal-binding domains (MBDs) of ATP7A/
B [14–16]. Single molecule FRET (sm-FRET) was used
to obtain kinetic information on Cu(I) transfer from Atox1
to ATP7B [17]. Electron paramagnetic resonance (EPR)
spectroscopy has been used to characterize the various
conformational states of Atox1 in solution while interact-
ing with its partner proteins [18]. Moreover, ultraviolet-
visible spectroscopy (UV-VIS) experiments and cell
experiments were performed to target essential residues
for Cu coordination and function. Computational meth-
ods such as molecular dynamics (MD) simulations, rely-
ing on force fields, have been applied to explore the free
energy landscape of protein monomers and dimers medi-
ating Cu transport [19], whereas mixed quantum classical
simulations (QM/MM), able to overcome limitations of
predefined force fields, have been employed to properly
characterize metal Cu(I) coordination to these proteins, as
well as its reaction/transfer mechanism [20].
Copper uptake by the transporter hCtr1
In 1997, Zhou and Gitschier became the first to identify a
human gene for copper uptake, hCTR1. They showed
that each hCtr1 polypeptide contains 190 amino acids
[21]. Ten years later Unger et al. [22,23] reported a three-
dimensional, 6-Å-resolution structure of hCtr1 using cryo-
genic electron microscopy; they showed that the protein
is a trimer containing: (1) 60 amino acids in the extracel-
lular N-terminal domain; (2) three transmembrane (TM)
helices (TM1, 2, and 3); (3) an intracellular loop of
46 amino acids, connecting TM1 and TM2; and (4) a
short intracellular C-terminal domain with 15 amino acids
(Figure 2).www.sciencedirect.com The extracellular domain of hCtr1 is characterized by several
motifs: glycosylation sites, histidine (His)-rich sites, and
methionine (Met) motifs. There are two glycosylation
sites in hCtr1: N15 and T27. N15 is not required for
function [24]. Conversely, when O-glycosylation at T27
is prevented, the first 30 amino acids of hCtr1 are cleaved
[25].
The His-rich sites in the extracellular domain of hCtr1—
comprising two motifs, 1MDHxHH and 22HHH—are
suggested to serve as Cu(II) binding sites. This idea is
supported by UV-VIS experiments showing that the
extracellular part of hCtr1 can bind two Cu(II) ions
[26]. EPR spectroscopy experiments suggest that the
process by which Cu(II) is transferred from the blood to
hCtr1 involves the blood carrier protein human serum
albumin (HSA), as reflected in evidence of close inter-
actions between HSA and the N-terminal domain of
hCtr1 [27].
The Met-rich motifs in the extracellular domain—two
segments, 7MxMxxM and 41MMMxM—are shared by
many proteins involved in Cu(I)-metabolism; these seg-
ments bind Cu(I) with mM affinity [28], and they are
essential for hCtr1’s recruitment of Cu(I), produced
through the reduction of Cu(II) [29,30]. Du et al. used
UV-VIS titrations to show that three Cu(I) ions can
coordinate to the extracellular part of hCtr1 [26]. A
combination of EPR, NMR, and UV-VIS experiments
performed on the first 14 residues of hCtr1 indicated that
H5 and H6 form the first Cu(II) binding site, whereas M7,
M9 and M12 constitute the first Cu(I) binding site [31].
Notably, the mechanism of the Cu(II)-to-Cu(I) reduction
process remains unclear. It has been suggested that
copper and iron metabolism are intimately linked, with
the two metals mutually participating in each other’s
oxidation/reduction reactions. This proposition is sup-
ported by observations that in the yeast Saccharomyces
cerevisiae, both Cu(II) and Fe(III) are reduced in the
plasma membrane by Fre1 or Fre2 [32,33], and both
Cu(I) and Fe(II) are oxidized (to Cu(II) and to Fe(III),
respectively) by Fet3 metalloxidase [34,35].
The TM domain of hCtr1 is characterized by conserved
150MxxxM and 167GxxxG motifs. De Feo et al. identified
M150 and M154 in TM2 as Cu(I)-binding residues,
whereas G167 and G171, both located in TM3, were
proposed to mediate a tight interface between TM1
and TM3 [23]. Schushan et al. constructed a Ca-trace
model of the TM domain of hCtr1, which agreed well
with the experimental structure [36]. Using a Gaussian
network model and an anisotropic network model, they
identified possible functional motions of the TM helices.
On the basis of these motions, the authors proposed
a transport mechanism in which the Cu(I) ions are
transferred one at a time, and M154 (which points toCurrent Opinion in Structural Biology 2019, 58:26–33
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hCtr1 monomer sequence. Special residues are marked with distinct colors.the extracellular part of the membrane) along with H139
and E84 (conserved residues) control the transporter’s
motion as a function of metal ion binding and a pH shift.
This model is supported by biochemical experiments
showing that H139 and E84 are indeed important func-
tional residues [37,38]. Tsigelny et al. used all-atom
simulations to develop a model for the full structure of
hCtr1 [39]; using a Ca trace approach, they suggested that
M43, M45, M150, and M154, and the 188HCH motif in
the C-terminal domain are important residues for Cu(I)
binding.
The intracellular domain of hCtr1 contains two parts: an
intracellular loop between TM1 and TM2, and a short
C-terminal tail. The last 15 residues, ending with a
188HCH motif, are essential for Cu(I) transport. Kaplan
and co-workers used 64Cu cell experiments to show thatCurrent Opinion in Structural Biology 2019, 58:26–33 C189 is notessential forCu(I) uptake [24],but that 188HCH
residuesare vital for transfer and regulation purposes [37]. In
the intracellular domain C189 was found to be critical for Cu
(I) binding and transfer to Atox1 [37,40]. NMR experi-
ments revealed that Cu(I) binds to 188HCH with high
affinity (KD of 10
14 M) [41]. As a result, Cu(I) can be
released to its target by protein–protein interaction, while
being unable to freely dissociate from hCtr1. A recent study
thatusedEPRalongwith circulardichroism(CD)andNMR
[42] showed that the intracellular loop can form a second
low-affinity Cu(I)-binding site (KD 1–10 mM) involving
the residues M106, M117, and H120.
Distribution of Cu(I) by the metallochaperone
Atox1
Atox1, also called Hah1, is a soluble protein (68 amino
acids), displaying a babbab fold [13]. It coordinates onewww.sciencedirect.com
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(a) Proposed mechanism for Cu(I) transfer from Atox1 to MBD4. (b) Representative structure obtained by MD for the interaction between holo-
Atox1 and MBD4. (c) The structure and electrostatic potential surface of holo-Atox1 monomer and MBD4.Cu(I) ion with the cysteine residues of a conserved
10MxCxxC motif (Figure 3). Cu(I)’s binding affinity
toward Atox1 is even higher than that for the C-terminal
domain of hCtr1 (KD = 10
17.4 M), enabling Cu(I) to be
transferred from hCtr1 to the metallochaperone [43].
Data obtained from the crystal structure of Atox1, as well
as from NMR experiments and QM/MM simulations,
point to additional residues, besides the conserved
Cys-based motif that are important to Atox1 function.
Specifically, K60 was found to be important for neutral-
izing the negative charge in the Cu(I) binding site, and
T11 was shown to contribute to the Atox1’s flexibility
[44–46]. Additionally, M10, completely conserved across
different organisms, is buried in the hydrophobic core,
contributing to Atox1’s stability [47]. Far-UV CD titration
experiments in the pH range 6–11 showed that Cu(I)
affinity for Atox1 decreases with the pH level, owing to
protonation of the cysteine residues in the binding site
[48]. Considering that hypoxic malignant cells arewww.sciencedirect.com characterized by low pH, this finding might point to a
mechanism by which cancer interferes with Cu-homeo-
stasis [49,50].
Notably, sm-FRET experiments have demonstrated that
Atox1 can assume two conformational states, both able to
interact with the target protein ATP7B [17]. EPR
measurements together with computations have resolved
these two conformational states [18,40,42], further sug-
gesting that Atox1 can adopt conformations specific to its
target protein. EPR experiments have also revealed the
importance of 188HCH in stabilizing the complex com-
prising the C-terminal tail of hCtr1 and Atox1 [40], and
have confirmed that Atox1 interacts with the intracellular
domain of hCtr1 (both the C-terminal tail and the intra-
cellular loop) as a homodimer. The Atox1 homodimer has
been solved by X-ray studies showing that the Atox1
dimer is stabilized by metal-mediated interactions, and
by complementarity in the electrostatic interactions
between the two monomers [44].Current Opinion in Structural Biology 2019, 58:26–33
30 Biophysical and computational methodsCu(I) uptake by the metal-binding domains of
ATP7B
ATP7B is made of eight TM segments and two large
cytosolic domains: (i) the N-terminal Cu-binding domain,
and (ii) the catalytic ATP hydrolyzing domain [51]. Over
300 mutations in ATP7B have been identified that affect
its function, indicating that almost one-third of the
encoded residues are strictly required for proper ATP7B
function. These observations suggest that, beyond iden-
tifying point mutations that affect Cu-homeostasis, it is
necessary to obtain a detailed mechanistic picture of Cu
(I) transfer in order to unravel the molecular basis of its
metabolism.
Atox1 interacts with the N-terminal domain of ATP7B,












hCtr1-Atox1-ATP7B Cu(I) transfer model. Atox1 plays a critical role in media
state and adjusting a specific conformation based on its target protein.
Current Opinion in Structural Biology 2019, 58:26–33 the Atox1 metallochaperone, each MBD has a ferredoxin-
like fold with a compact babbab structure and a con-
served metal-binding motif MxCxxC, located in the
solvent-exposed b1-a1 loop. On the basis of the struc-
tures of Atox1 and of an MBD of ATP7B, Wernimont
et al. proposed a mechanism for Cu(I) transfer from Atox1
to the MBD (Figure 3). In this model Atox1 transfers Cu
(I) to a single MBD through consecutive ligand exchange
reactions [44]. Subsequent studies used biophysical and
computational methods to characterize the interactions
between Atox1 and the six MBDs of ATP7A/B, focusing
mostly on MBD4. NMR studies showed that the six
MBD units (MBD1–6) can be differentiated into two
groups, comprising MBD1–3, and MBD5–6, with MBD4
serving as a linker between them [14,44,52]. The struc-
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ting Cu(I) transfer mechanism, cycling between a dimer to monomer
www.sciencedirect.com
Copper cycle Magistrato et al. 31[15,53]. Of all the MBDs, Atox1 interacts most strongly
with MBD1-MBD4, whereas it does not interact with
MBD5 or with MBD6 [14,16,54,55]. Cu(I) binding to
regulatory MBD1–4 stimulates its transport by ATP7B
and presumably facilitates the trafficking of the trans-
porter by exposing sites for further modifications and
protein–protein interactions [15,56]. However, NMR
studies and MD simulations revealed an exclusive inter-
action between Atox1 and MBD4, and not with MBD3
[19,54]. Whereas, smFRET experiments identified a
dynamic situation in which, because of its structural
flexibility, Atox1 can coordinate either MBD3, MBD4,
or the two domains simultaneously, MBD3–4 [17]. A
recent study by our group, relying on a combination of
EPR and MD simulations, revealed that Cu(I) extrusion
is most likely mediated by Atox1 binding to MBD4 via
the formation of transient interactions mediated by elec-
trostatic complementarity of the two surfaces. Regarding
the chemical mechanism, Cu(I) appears to be transferred
by ligand exchange from C12/C15 of Atox1 to C370/C373
of MBD4 via the formation of several intermediates
displaying a three-coordinated Cu(I) site (Figure 3).
QM/MM simulations suggest that K60 of Atox1 may
actively modulate the Cu(I) exchange [54]. All these
experiments indicate that Atox1 interacts with MBDs
in a monomeric state [57,58], in contrast to its interaction
with hCtr1, as a dimer (Figure 3). Figure 4 shows a
mechanistic picture of Cu(I) transfer from hCtr1 to
MBD of ATP7B based on the current knowledge.
Conclusions
In recent years, significant progress has been made toward
elucidating the mechanisms underlying intracellular cop-
per regulation. Multiple distinct studies have consistently
revealed that the methionine segments and cysteine-
based motifs present in the various components of the
hCtr1-Atox1-ATP7A/B cycle are critical for Cu(I) bind-
ing. Studies investigating the effect of pH on Cu(I)
affinity to proteins have provided critical insights regard-
ing the possible mechanisms of cysteine ligand exchange
reactions underlying metal transport. Discoveries regard-
ing the conformational flexibility of Atox1, together with
its capacity to function either in a dimeric or monomeric
form, depending on its protein partner, indicate how the
metallochaperone elegantly mediates Cu(I) transfer from
hCtr1 to the Golgi apparatus and/or to its excretion route.
In spite of these achievements, many gaps remain in our
understanding of this important metabolic pathway. In
particular, knowledge of the mechanisms underlying
hCtr1 and ATP7A/B function remains fragmentary, owing
to the challenges involved in expressing and purifying
these proteins for biophysical research, and in resolving a
structural model at atomic-level resolution. It is necessary
to overcome these obstacles, using a combination of
biophysical, biochemical, and computational approaches,
in order to identify all Cu(I) binding sites, and to obtain awww.sciencedirect.com comprehensive understanding of the Cu(I) transfer mech-
anism. As discussed above, current experimental and
computational data suggest that each MBD in ATP7B
has a specific role; these observations should be further
analyzed and confirmed on the full-length ATP7B.
A more complete understanding of hCtr1-Atox1-ATP7A/
B cycle may contribute toward the development of treat-
ment for diseases associated with Cu-metabolism dys-
function, including Menkes’ and Wilson’s diseases. Cur-
rent treatment for these conditions relies on Cu-chelators,
which have led to an increased lifespan in some patients,
yet are not uniformly effective. Moreover, although
numerous studies have identified connections between
copper regulation and neurological diseases such as
Parkinson’s, Alzheimer’s and prion diseases, the under-
lying mechanisms of these connections remains elusive.
Similarly, the role of Cu-transport and homeostasis in
cancer, and in resistance to commonly used metal-based
anticancer drugs, remains unresolved [9,10].
Herein, we have sought to depict current understanding
of the Cu-transfer mechanism at the atomic level, empha-
sizing the delicate balance of transient protein–protein
interactions underlying metal transfer, reactivity, and
homeostasis. It remains a daunting challenge to harness
this knowledge for future innovative therapeutic
approaches aiming at counteracting the many pathologi-
cal states associated with Cu-dis-homeostasis.
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